10:31
Where are stem cells now and what is next?
St Mark's Academic Institute
Overview
This video discusses the current status and future potential of stem cells for treating complex perianal Crohn's fistulas. While initial studies like the Admire trials showed promise, mixed results, particularly the failure of the second trial (Admire CD2), have led to skepticism. The speaker explores reasons for these discrepancies, including patient selection and donor variability, and highlights ongoing research into biological augmentation as a more promising avenue for improving surgical outcomes in managing these challenging conditions.
How was this?
Save this permanently with flashcards, quizzes, and AI chat
Chapters
- Perianal Crohn's disease can lead to complex fistulas that are difficult to treat.
- The 'Class 2A' classification identifies fistulas with surrounding tissue suitable for repair attempts.
- Fistulas can be categorized as suitable for anatomical repair (e.g., flap, LIFT) or non-anatomical repair (for more complex cases).
- Previous treatments for complex, non-anatomical fistulas had limited success.
Understanding the classification of fistulas is crucial for selecting the most appropriate surgical approach and managing patient expectations.
Class 2A perianal Crohn's fistulas are the focus, specifically those where the surrounding tissues allow for a repair attempt.
- Mesenchymal stem cells have anti-inflammatory and tissue-repair properties, making them theoretically ideal for fistula treatment.
- The Admire CD1 trial showed a modest benefit for stem cells over saline injection in closing fistulas.
- The subsequent Admire CD2 trial, conducted in the US, failed to replicate these positive results, showing no significant difference between stem cells and the control.
- Discrepancies between trials may be due to differences in patient populations (e.g., use of other medications) and stem cell donor variability.
The mixed results from clinical trials highlight the complexity of using stem cells and the need for careful patient selection and cell characterization.
The Admire CD1 trial showed a 16% difference in healing rates between stem cell treatment and saline injection, while Admire CD2 did not find this difference.
- Despite some positive real-world data and ongoing research into biological mechanisms (like stem cell apoptosis), the widespread use of stem cells for fistulas has stalled.
- Regulatory hurdles and the failure to consistently demonstrate efficacy have contributed to this decline.
- The idea of 'giving stem cells badly' by using the wrong patients or donors might explain the inconsistent trial outcomes.
- The focus has shifted from a 'magic bullet' approach to understanding the underlying biology of fistula persistence.
This shift signifies a move away from broad application towards a more targeted, biologically informed approach to treatment.
Research suggesting that higher stem cell apoptosis in patients with a high level of response implies a biological effect that could be leveraged.
- The future likely lies in 'biological augmentation' to enhance surgical repair of complex fistulas.
- This involves adding biological agents to standard surgical techniques (like LIFT or flap) to counteract the hostile environment that prevents healing.
- Early attempts with fibroblasts were unsuccessful, but other options are being explored, including stromal vascular fraction and platelet-rich plasma.
- Autologous adipose tissue (fat) is a promising area, with studies showing good results in fistula healing.
- The ultimate goal is to understand the root causes of fistula formation and persistence to identify the most effective biological augmentations.
Biological augmentation offers a more nuanced and potentially effective strategy for improving healing rates in complex fistulas by addressing the local disease environment.
Using liposuctioned fat from the patient and injecting it during fistula repair has shown positive results in early studies.
Key takeaways
- Stem cells, while theoretically promising for tissue repair, have not consistently proven effective for complex perianal Crohn's fistulas in large clinical trials.
- Variability in patient populations and stem cell donors likely contributed to the conflicting results between the Admire CD1 and CD2 trials.
- The concept of 'biological augmentation' is emerging as a more promising strategy to improve surgical outcomes by modifying the local tissue environment.
- Understanding the underlying biology of fistula formation and persistence is key to developing targeted and effective treatments.
- While stem cells may not be the 'magic bullet,' the principles behind their potential therapeutic effects are driving research into other biological agents.
- Future treatments will likely combine advanced surgical techniques with specific biological interventions tailored to the individual patient's condition.
Key terms
Perianal Crohn's fistulaClass 2A fistulaAnatomical repairNon-anatomical repairMesenchymal stem cellsAdmire CD1 trialAdmire CD2 trialBiological augmentationStromal vascular fractionAutologous adipose tissue
Test your understanding
- What are the two main categories of surgical repair for perianal Crohn's fistulas, and why is this distinction important?
- Why did the Admire CD1 and Admire CD2 trials yield different results regarding the efficacy of stem cell therapy for fistulas?
- How does the concept of 'biological augmentation' differ from the initial approach of using stem cells for fistula treatment?
- What are some examples of biological agents being investigated for fistula treatment besides stem cells?
- What is the ultimate goal of understanding the 'etiology and persistence' of fistulas in the context of developing new treatments?